RECEIVED **CENTRAL FAX CENTER**

AUG 1 2 2005

PTO/SB/22 (12-04)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patant and Tradomark Office; U.S. DEPARMENT OF COMMERCE
a collection of information unless if displays a valid OMB control number,

DETITION	FOR EXTENSION OF TIME	Docket Number (Optional)		
PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2005			Z70599-1P US	
(Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)				
Application Number 10/088,814			Filed September 4, 2002	
For Quinazoline Derivatives and Their Use as Pharmaceuticals				
Art Unit 1624			Examiner Tamthom Ngo Truong	
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filling a reply in the above identified application.				
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):				
,	One month (37 CFR 1.17(a)(1	<u>Fee</u> i) \$120	Small Entity Fee \$60	•
		•	•	s 450.00
X	Two months (37 CFR 1.17(a)(2)) \$450	\$225	
	Three months (37 CFR 1.17(a	(3)) + \$1020	\$510	\$
	Four months (37 CFR 1.17(a)(\$)) \$1590	\$795	\$
	Five months (37 CFR 1.17(a)(5)) \$2160	\$1080	s
Applicant claims small entity status. See 37 CFR 1.27.				
A check in the amount of the fee is enclosed.				
Payment by credit card. Form PTO-2038 is attached.				
The Director has already been authorized to charge fees in this application to a Deposit Account.				
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number50-3231 I have enclosed a duplicate copy of this sheet.				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
I am the	applicant/inventor.			
assignee of record of the entire interest. See 37 CFR 3.71.				
Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96). The statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96). The statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96). The statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).				
attorney or agent under 37 CFR 1.34, Registration number if dicting under 37 CFR 1.34				
	Nucusadae		August	12,2005
	Signature		Date	9
Lucy Clare Fadget			+1 781 839 4182	
	Typed or printed n	ime	Telephone	Number
NOTE: Signatures of all the inventors or assignoes of roc and of the entire interest or their representative(e) are required. Submit multiple forms if more than one signature is required, see below.				
X Total		forms are submitted.		
This collection of information is required by 97 CFR 1.135(s). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including case. Any				

comments on the amount of time you require to complete it is form and/or suggestions for reducing this burden, should be sent to the Chief information Offi U.S. Patent and Trademark Office, U.S. Department of Cor Imerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

08/15/2005 SSITHIB1 00000014 503231

10088814

01 FC:1252

450.00 DA